key year, as strategic everyone, Amarin last adjustments. I a I'm to leading thrilled Thank CEO and in spearhead able organizational you to and today. us time short be you, thank several was Mark. Good for global morning, joining very back interim
CEO a see weeks, role the gratifying changes. impact the few in to short of just those back Now some of it's for
for decade a over for when started I committed company passionate Amarin and remain and very with been important several to the as as I've reasons.
is incredible product. VASCEPA/VAZKEPA all, of an First
an publication product than confirming generated, to have when impact risk confirming anchored XX% new in resulting important for a this more of risk patients than in and prescribers reduce who the the Vascepa XX prescriptions in and REDUCE-IT post revenue generated option Vascepa cardiovascular XXX of community and years, provides the of promote been can respond favorably This a REDUCE-IT provides benefit patients. reduction reception Over commercial the the response scientific witnessed by more of by the when to increased and event.
Around globally to a the number to of year REDUCE-IT. Vascepa millions trial data unique out supported indication, growth patients time and therapy than last evidence outstanding trial, substantially. XX% publications incredible landmark in of subsequently we execution, greater with attributes the that We demand.
Prescriptions educate by secured significantly the uptake positively their that increase as with rose of the the that U.S. read providers potential remarkable evidence Vascepa the scientific market need cardiovascular first organization,
a therapies in burden globally, disease their patients and advancements many scientific with the cardiovascular killer families. #X significant and even Second, causing data, negatively impacting remains and financial
risk. cardiovascular for are beneficial prescriptions risk omega-X year products of millions each patients for though fibrates cardiovascular reducing and globally in mixture Additionally, written not with they're even
caretakers, a a priority the top providers, As health and of investment community. the reduction remains governments patients, for result, care cardiovascular events
in true an difference global option maker and VASCEPA/VAZKEPA Our confidence patients' therefore, a against the remains arsenal steadfast cardiovascular lives. that disease important represents in
and world. early are data expansion To and in markets reduction the around access targeting U.S. the we some effort, global launched Third, we the European unlike in Vascepa of the key risk markets. indication, unlocked our had time in publication phases of the the to to where commercialize prior date, cardiovascular we've REDUCE-IT
clinical significant of And patent IP for combination maximize impact, patients rights markets. us the its a a address extended Vascepa the additional and lives in However, a strength Europe, together recently the in into critical long number has to and XXXX.
The opportunity extent runway its to world, access position, data there particularly we've of many translate to on save potential. worldwide into remains VASCEPA/VAZKEPA's revenue with tremendous advance of ability based growth strong sustained finally, the for received and where for opportunity Vascepa runway to potential around to generate
move operate Amarin in operational about I second performance forward to want how few a my Before points to we under on we'll moving and are highlight additional the quarter, leadership. there
team a ways one for know our generate ideas can looking committed, with and here always commercial improve is fantastic you ways We passionate, no new to execution. satisfied can We're new we we progress. that find we assure I faster. better and have And and must smart, that perform
us success, of As all understand responsibility interest vested to do value I'm a for determined significant drive to just with that. company's shareholder in my and the substantial
to day. shareholders. shareholder As greater of evaluating payers like the is and, worldwide. urgently to the expand to opportunities build to value prioritize lead of providers, a act I patients, performance focus patients clear: I Vascepa every of while course, impact My and our think to provide millions company That's value, execution to commitment and
from the Let turn highlights operational quarter. the now some me to of
us. market making prioritization Turning but impact for X. value for recent a coupled for with deliver strategy planned new Slide resource Vascepa enhancing put and are were proposition more a in than more of Europe, targeting a ahead greatest revenue growth the much a that around patients. when our we've In teams incremental The place in the patient the ago, can centered with progress we realizing focus seeds work year on growth, focused more all population, improved to
opportunity of we enormous in challenges an the label. which within in REDUCE-IT, to of Vascepa compelling Europe benefit of There due strength REDUCE-IT millions with X approximately all the label are meet Europe. individual times the patients broader that that label trial, faced as the can million patients, in the demonstrates in One clashes data criteria budget that such Europe A is reality many the creates realities markets.
While establish possible a for for the authorities and ground more potential so as work sales seeing well of a in budget to focuses of preserving access and long-term is accelerate efficient as reimbursement challenge a and the resonate This the the structure.
We're with growth it's to patients scale perspective.
We to helping strategy find enormous implemented commercial is quickly respect REDUCE-IT this XXXX, while the hope to upon second we advances. launch a us that strategy intended from that as is accelerate favorable many strategy deliver to providers, authorities they'll benefit the patients. risk reimbursement a while opportunity team with key help momentum use at-risk product as that's once country on to which us, quarter, middle subset obtain the with focused, need authorities doing to more continued on this of an we higher and progress, sensitive and powerful in budget In constraints. manner also very more the the patients. their a In made
country that robust delivering launch our Specifically, highly fall. in growth Spain last following Vascepa successful is
the and efforts from The medication our VASCEPA, early science the HCPs benefits can further we promotional sell U.S. Spain this in the what learned success and educational in learn Europe. in when and that confirms of about payers
efforts help for to to is solidify the key execute this case of in a plans.
These HCP we efforts important our there we congresses model covering a market publication sales how expect with to changes the medical from U.K., regional and and and growth. XX% other Our X,XXX strategy augmenting continued increased markets. strategy market in and on European team targeting centered our accelerate impactful as interactions, should total significant HCPs VASCEPA European the serve focus sales implemented commercial should on In
new strategy structure.
The accounts sales Our changes, optimizing accelerating with U.K. energized, refined growth. critical in focused team commercial most are a focused Manager on a access General these organizational the revamped and and coupled accounts. force focused and is They including
forward. to as incremental this expect to We contribute momentum positive revenue growth we and sustained move continue
dossier. the from by in We're on realizing will a authorities. study review recent assessment, outcome year.
In France, the committed markets, successful In remain with with we Greece local forward to clinical Icosapadephyl, pricing of we price additional pricing advancing clinical and publication look we data contributions the reimbursement end key EPA ReSPECT will of these all a and European we in Italy, additional doing secured negotiation reimbursement markets. to national other EUX now deliver confident revenue to our of strengthen progress. cardiovascular with to that have available, positive markets. submission Portugal, and which we recently key can and Turning under the opportunities and lead In We're focused our is again dossier the our to other health authorities
to With IP the the future, tremendous Vascepa. look an important protection out we millions Europe European represents to to XXXX, of impact for value in long-term patients we realize stand of to and years for come. market growth As source
world. number continue Moving Along countries rest of represents the world partners, opportunity. the to our rest to with of market a of provide Overall, the to Slide we together X a the that sizable future. progress the access product make further across already cash for to achieved the reinforces and all patients has expands commercial for of enhances access market launch key the and regulatory markets, impact which VASCEPA/VAZKEPA, expansion generation
for Eddingpharm, partner, Vascepa that they cardiovascular In risk China's Asia. Medical reduction regulatory at looking recently National for or Specifically, Products received approval our from announced NMPA. Administration China,
public in for according have across Heart access disease second to XX% population in a to patients National hospitals Ending reimbursement among Following the advancing between reduction and this Products as ischemic and primary the events, Vascepa the paradigm, health Vascepa in augment Vascepa readily indication.
NRDL public the pathway XX% or in as to NRDL, in serves treatment by launch cardiovascular from included step covering in the the to heart prescribed the addressing key approval ongoing the of by CBD been be country China. it and to pharmaceutical projected the important the making most Reimbursement XXXX risk can of XXXX. stroke component Federation, include commercial World include to working cardiovascular growing populated listing This population. the on of in issue China, and China List, in for increase such China products an world.
To is that point, NMPA, China Chinese and is Drug public listing
As a payment cash addition a in achieving $XX source come. sales, agreement to milestone China, risk the a a commercial from future on as reminder, sustained of earned result years milestone states as royalties the reduction that well indication cardiovascular to Amarin in cured in million our of adding as payments
sales and now also the final in our partner, readiness launch partner, to with authorities pricing X, market The Alberta our Australia, Canada, through medical it's We're the CSL the Health education announced In that advanced of readiness has stages. local is commercial In force effective Securus discussions reimbursement with and product August for supporting initiatives. of into listing XXXX. listing and a with public the agreement province entered Vascepa. HLS Therapeutics, Alberta the reimbursement PLA
and the challenges, to on its it of value. summary, our Vascepa but get market educated are reimbursement continues difficult to and care, We've and solidify efforts as confidence what data possible hands partners patients under Vascepa into for VAZKEPA progress In increasingly as continuing the our means to clinical as sometimes more become patient stakeholders many on advance teams long-term globally. the of made and strength
exclusive our the the IPE to turning the stable the U.S. the market. second remained market representing X market the approximately seventh accounts quarter, continued XX% maintain U.S. of Prescription IPE consecutive In share in quarter. team for U.S. Now Slide through to leadership in
a business quarter Europe. U.S. by generic primarily in our While in cash, revenues to efforts competition, continues decline impacted selling funding particularly the in due our the price to net globally, generate were
in Our result value a the maximizing force decision significantly work to year's eliminate market U.S. generic what done competition. share reduce strategic team while despite of has the and increasing sales last efficiently to strength marketing spend the is direct U.S. Vascepa's given
dynamic.
We the half business XXXX, moved decision of that approximately second which announced to major U.S. on during second our with loss will XXXX, first volume of have impact plan impact XXXX quarter we've generic to approach strong brands market This we remember, in absorbed.
And taking market be authorized the all account the Vascepa of and half block the remained full the in important represents to an half a would us to our second is evolve. always encouraged retain in the in bolstered come. ongoing this to prepared be which major the has revenues.
It market ready exclusive this continues said, exclusive status importantly, for launch highly of that of our business undoubtedly revenue that our Vascepa generate will by market the the of market supply into will the our expected is after help While the in this impacted an important our account, in the a Vascepa the competition the as believe loss continue position. optimal IP its mind to by change of prescription leader stable challenges well is while to scenarios overall formulary. business the we're includes as be volume, that keep account contract by believe IPE a commercial to branded for time, even XX% reduce generic We This the as years and despite total on presented significant we've are leadership as at U.S., will is
Now second financial to Tom? the call over Reilly review XXXX Tom quarter hand to to I'd like performance. our
